吉西他滨联合顺铂一线治疗晚期三阴乳腺癌疗效分析  

Efficacy of GP regime as first-line chemotherapy on advanced triple negative breast cancer

作　　者：王蓓[1] 王淅[2] 吕晓皑[1] 

机构地区：[1]浙江省中医院乳腺病中心,浙江杭州310006 [2]上海交通大学医学院,上海200025

出　　处：《实用肿瘤杂志》2011年第5期507-509,共3页Journal of Practical Oncology

基　　金：浙江省卫生厅基金(2010KYA149)

摘　　要：目的分析吉西他滨联合顺铂(GP方案)治疗复发转移性三阴乳腺癌的反应率及不良反应,进一步了解该方案治疗可获取的疾病进展时间(TTP)和总生存时间(OS)。方法回顾性分析住院治疗的35例晚期三阴乳腺癌。所有患者均一线接受GC方案(吉西他滨针1 000 mg/m2,d1、d8+顺铂针25 mg/m2,d1-3,每21天重复)化疗。患者每2周期接受疗效评价。统计肿瘤反应率和不良反应,通过后续随访,统计TTP和OS。结果 35例晚期三阴乳腺癌,均有可评价病灶。21例继往接受了含紫杉类药物辅助化疗,14例患者继往接受了含蒽环类药辅助化疗。入组后患者共接受2～6周期GP方案化疗,中位数为3.8周期。完全缓解(CR)2例(5.7%),部分缓解(PR)10例(28.6%),疾病稳定(SD)6例(17.1%),疾病进展(PD)7例(20.0%),总反应率(ORR)为34.3%。中位TTP为7.0月,中位OS为13.0月。结论晚期三阴乳腺癌接受GP方案化疗有较高反应率,耐受性好,但TTP较短,生存时间有限,需要寻找更为有效的治疗靶点。Objective To explore the effect and toxicity of GP regime in patients with triple negative（TN） breast cancer,and further to test the time to progress（TTP） and overall survival（OS） of this treatment. Methods Thirty-five patients with advanced triple negative breast cancer,who received GC regime between July,2000 and July,2006 were retrospectively reviewed.All subjects taking first-line chemotherapy with GC regime received a 21-day cycled chemotherapy,gemcitabine 1 000 mg/m2,d1,d8 and cisplatin 25 mg/m2,d1-3.Patients were evaluated for their tumor response every 2 cycles.The rates of tumor and toxicity were compared using time to progression（TTP） and overall survival（OS） in the follow-up. Results Identified mass could be evaluated among all 35 advanced triple negative breast cancer patients.Of the 35 patients,21 patients had previously undergone the adjuvant chemotherapy with anthracycline and taxane,while other 14 patients were treated with anthracycline agent.During the experiment,all of them received 2~6 cycles（median 3.8 cycles） chemotherapy.Two patients（5.7%） had complete remission（CR）,10（28.6%） partial remission（PR）,6（17.1%） stable disease（SD） and 7（20.0%） progressive disease（PD）.The overall reaction rate（ORR） was 34.3%.The median TTP was 7.0 months,the median OS was 13.0 months. Conclusions The advanced TN breast cancer patients treated with GP regime can achieve higher reaction rate with lower toxicity,but with poorer results in TTP and OS.More targeted and promising therapeutic agent calls should be found for further exploration.

关 键 词：乳腺肿瘤/药物疗法 吉西他滨/治疗应用 顺铂/治疗应用 回顾性研究 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]